MRM Health

About MRM Health

MRM Health develops therapeutics using its proprietary CORAL® platform, which combines selected bacterial strains into optimized consortia manufactured as a single drug substance. This approach addresses the challenges of engraftment and efficacy in microbiome-based therapies, particularly for inflammatory bowel diseases and other conditions.

```xml <problem> Current microbiome-based therapies face challenges in achieving consistent engraftment and efficacy due to the complexity of the gut ecosystem and the difficulty of manufacturing stable, multi-strain products. This limits their effectiveness, particularly in treating inflammatory bowel diseases and other chronic conditions. </problem> <solution> MRM Health is developing a new class of microbiome therapeutics based on rationally selected and optimized consortia of live bacteria. Their proprietary CORAL® platform combines 5-10 strains into a single drug substance, manufactured under GMP conditions, to ensure consistent composition and stability. This approach enhances engraftment, promotes a faster onset-of-action, and delivers a superior efficacy profile compared to existing microbiome therapies. The company's therapeutics are designed to have a sustained impact on disease, with a focus on inflammatory, CNS, and metabolic diseases. </solution> <features> - CORAL® platform for rational selection and optimization of bacterial consortia - Fully characterized consortia of 5-10 safe and effective strains - Proprietary Microbiome Optimization Technology for enhanced therapeutic impact - GMP-compliant manufacturing process for producing consortia as a single drug substance - Access to the SHIME® simulator for advanced in-human gut modeling - End-to-end development capabilities, from discovery to clinical development </features> <target_audience> The primary target audience includes patients suffering from inflammatory bowel diseases (IBD) such as ulcerative colitis and pouchitis, as well as those with CNS disorders like Parkinson’s Disease, metabolic diseases such as Type 2 Diabetes and NAFLD/NASH, and auto-immune diseases like Spondyloarthritis. </target_audience> ```

What does MRM Health do?

MRM Health develops therapeutics using its proprietary CORAL® platform, which combines selected bacterial strains into optimized consortia manufactured as a single drug substance. This approach addresses the challenges of engraftment and efficacy in microbiome-based therapies, particularly for inflammatory bowel diseases and other conditions.

Where is MRM Health located?

MRM Health is based in Gent, België / Belgique / Belgien.

When was MRM Health founded?

MRM Health was founded in 2020.

How much funding has MRM Health raised?

MRM Health has raised 24570000.

Location
Gent, België / Belgique / Belgien
Founded
2020
Funding
24570000
Employees
41 employees
Major Investors
SFPIM

Find Investable Startups and Competitors

Search thousands of startups using natural language

MRM Health

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

MRM Health develops therapeutics using its proprietary CORAL® platform, which combines selected bacterial strains into optimized consortia manufactured as a single drug substance. This approach addresses the challenges of engraftment and efficacy in microbiome-based therapies, particularly for inflammatory bowel diseases and other conditions.

mrmhealth.com2K+
cb
Crunchbase
Founded 2020Gent, België / Belgique / Belgien

Funding

$

Estimated Funding

$20M+

Major Investors

SFPIM

Team (40+)

No team information available.

Company Description

Problem

Current microbiome-based therapies face challenges in achieving consistent engraftment and efficacy due to the complexity of the gut ecosystem and the difficulty of manufacturing stable, multi-strain products. This limits their effectiveness, particularly in treating inflammatory bowel diseases and other chronic conditions.

Solution

MRM Health is developing a new class of microbiome therapeutics based on rationally selected and optimized consortia of live bacteria. Their proprietary CORAL® platform combines 5-10 strains into a single drug substance, manufactured under GMP conditions, to ensure consistent composition and stability. This approach enhances engraftment, promotes a faster onset-of-action, and delivers a superior efficacy profile compared to existing microbiome therapies. The company's therapeutics are designed to have a sustained impact on disease, with a focus on inflammatory, CNS, and metabolic diseases.

Features

CORAL® platform for rational selection and optimization of bacterial consortia

Fully characterized consortia of 5-10 safe and effective strains

Proprietary Microbiome Optimization Technology for enhanced therapeutic impact

GMP-compliant manufacturing process for producing consortia as a single drug substance

Access to the SHIME® simulator for advanced in-human gut modeling

End-to-end development capabilities, from discovery to clinical development

Target Audience

The primary target audience includes patients suffering from inflammatory bowel diseases (IBD) such as ulcerative colitis and pouchitis, as well as those with CNS disorders like Parkinson’s Disease, metabolic diseases such as Type 2 Diabetes and NAFLD/NASH, and auto-immune diseases like Spondyloarthritis.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.